We are live on ! Find out more
FLNA

Filana Therapeutics
FLNA

33 hedge funds and large institutions have $9.98M invested in Filana Therapeutics in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 10

31.38% more ownership

Funds ownership: 5.3% → 36.68% (+31%)

15% less funds holding

Funds holding: 39 → 33 (-6)

35% less capital invested

Capital invested by funds: $15.3M → $9.98M (-$5.3M)

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

Holders
33
Holders Change
-6
Holders Change %
-15.38%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
15
Reduced
10
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$283K
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$81.3K
3
ARTA
A.R.T. Advisors
New York
+$55.7K
4
VKH
Virtu KCG Holdings
New York
+$43.3K
5
GS
Gagnon Securities
New York
+$41.6K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$203K
2
BlackRock
BlackRock
New York
-$150K
3
Renaissance Technologies
Renaissance Technologies
New York
-$128K
4
BCM
Bridgeway Capital Management
Texas
-$55.9K
5
TA
Teton Advisors
New York
-$40K

FLNA Hedge Fund Activity: Q2 2017 in Review

33 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2017, worth a combined $9.98M — down 35% from $15.3M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of FLNA and 4 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 15 added.

The largest buyer was Dimensional Fund Advisors, opening a new position worth an estimated $283K. The largest seller was Vanguard Group, cutting an estimated $203K.

  • 33 institutional investors held Filana Therapeutics (FLNA) as of Q2 2017, down from 39 in Q1 2017.
  • Funds reported $9.98M of Filana Therapeutics stock for Q2 2017, down 35% quarter-over-quarter.
  • 4 funds opened new Filana Therapeutics positions in Q2 2017 and 10 closed out, a net change of -6 holders.
  • The largest Filana Therapeutics buyer in Q2 2017 was Dimensional Fund Advisors, an estimated $283K added.
  • The largest Filana Therapeutics seller in Q2 2017 was Vanguard Group, an estimated $203K sold.

Based on aggregated 13F filings for Q2 2017.